Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have received an average rating of “Moderate Buy” from the twenty-three ratings firms that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $166.00.

Several analysts have issued reports on NBIX shares. Wedbush reissued an “outperform” rating and set a $148.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research note on Monday, September 16th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a report on Friday.

Neurocrine Biosciences Stock Up 0.3 %

NASDAQ:NBIX opened at $135.42 on Friday. Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98. The stock has a fifty day simple moving average of $123.99 and a 200 day simple moving average of $130.61. The firm has a market capitalization of $13.71 billion, a price-to-earnings ratio of 36.31 and a beta of 0.34.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the transaction, the insider now owns 2,507 shares in the company, valued at approximately $338,445. This represents a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.

Institutional Trading of Neurocrine Biosciences

A number of large investors have recently bought and sold shares of the business. Plato Investment Management Ltd lifted its stake in Neurocrine Biosciences by 2,481.9% in the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after acquiring an additional 10,548 shares in the last quarter. Swiss National Bank raised its position in shares of Neurocrine Biosciences by 1.4% in the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after purchasing an additional 4,100 shares during the period. Tri Ri Asset Management Corp acquired a new position in shares of Neurocrine Biosciences in the third quarter valued at approximately $3,236,000. KBC Group NV increased its position in Neurocrine Biosciences by 78.3% during the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after buying an additional 8,332 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in Neurocrine Biosciences by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock worth $2,238,000 after purchasing an additional 7,597 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.